Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Chief Financial Officer | February 19, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date February 19, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2030-06-08 | Direct | 594,890 |
Reported balance
After 2021-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-19 · Disposition to issuer · Disposed 5,110 · Balance 594,890 F1: Represents the forfeiture of performance-based stock options granted to the Reporting Person on June 8, 2020 that were eligible to vest based on certain performance conditions. Upon grant, the target vesting amount was reported in Table II of Form 3. On February 19, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that, based on the Issuer's performance over the applicable performance period, 37,129 shares would vest and 5,110 shares would be forfeited. F3: Not applicable. F2: As of February 19, 2021, a total of 79,368 shares have vested and 515,522 shares remain eligible to vest from this grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the forfeiture of performance-based stock options granted to the Reporting Person on June 8, 2020 that were eligible to vest based on certain performance conditions. Upon grant, the target vesting amount was reported in Table II of Form 3. On February 19, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that, based on the Issuer's performance over the applicable performance period, 37,129 shares would vest and 5,110 shares would be forfeited.
F2: As of February 19, 2021, a total of 79,368 shares have vested and 515,522 shares remain eligible to vest from this grant.
F3: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2021 Filed Feb 23, 2021 22:59 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Disposition to issuerStock Option (right to buy) · Derivative | 5,110 | Not disclosed Strike: $3.52 | Not disclosed |
DisclosureSEC source: 0000921895-21-000543 · form412566don_02232021.xml · derivative · entry 1 Donaldson Michael Paul · CIK 0001824022 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,890 Underlying: Common Stock · 5,110 shares Expires 2030-06-08 F1 · shares: Represents the forfeiture of performance-based stock options granted to the Reporting Person on June 8, 2020 that were eligible to vest based on certain performance conditions. Upon grant, the target vesting amount was reported in Table II of Form 3. On February 19, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that, based on the Issuer's performance over the applicable performance period, 37,129 shares would vest and 5,110 shares would be forfeited. F3 · price: Not applicable. F2 · derivative.exercise_date: As of February 19, 2021, a total of 79,368 shares have vested and 515,522 shares remain eligible to vest from this grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.